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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128 S115regimens vary and may affect treatment outcomes. In this
retrospective analysis, we investigated if IV busulfan dosing
(total dose 3.2 mg/kg vs. 6.4 mg/kg) in ﬂudarabine/busulfan
(Flu/Bu) RIC regimens would affect outcomes in patients
undergoing HCT for MDS or AML. A total of 217 patients with
MDS or AML underwent Flu/Bu RIC PBSCT fromwell matched
related or unrelated donors at our institutions between 2004
and 2009. 135 patients received Bu1 (busulfan 0.8 mg/kg/d x
4 while 82 patients received Bu2 (busulfan 0.8 mg/kg bid x
4), both with daily ﬂudarabine (30 mg/m2/d x 4 days). The
choice of RIC regimens was based on temporal institutional
standard, enrollment on protocols, and physician choice.
Patients had similar characteristics with a few notable
differences: patients receiving Bu1 were younger (median
age 61 vs 64, p<0.001), received more single-antigen mis-
matched unrelated grafts (14.1% vs. 1.2%, p<0.001), received
more sirolimus based GVHD prophylaxis regimens (63% vs
45%, p < .0001), received less ATG for GVHD prophylaxis (0%
vs. 22%, p < 0.001) and had less enrollment on a post-HCT
clinical trial using prophylactic rituximab for the prevention
of chronic GVHD (2.2% vs. 11.0%, p¼0.011). Clinical disease
status was similar between the two groups. Median follow-
up for survivors was 4.4 years for Bu1 and 3.2 years for Bu2.
Due to the differences in characteristics, the two groups were
compared with the adjustment of a propensity score pre-
dicting Bu2 to account for measured differences. The day
þ200 cumulative incidence of grades II-IV acute GVHD (Bu1
17% vs Bu2 8.5%, HR 0.56 [0.22, 1.41], p¼0.22) or grades III-IV
acute GVHD (Bu16.7% vs. Bu2 4.9%) were not different. The 2-
year cumulative incidence of chronic GVHD (Bu1 41.5% vs
Bu2 28%, HR 0.70 [0.42, 1.17], p¼0.09) was not signiﬁcantly
different. 2-year non-relapse mortality (NRM) was similar
(Bu1 8.9% vs Bu2 9.8%, HR 0.80 [0.29, 2.21], p¼0.67). 2-year
progression-free survival (Bu1 40.6% vs Bu2 39.3%, HR 0.82
[0.57, 1.30], p¼0.33) and overall survival (Bu1 47.4% vs Bu2
48.8%, HR 0.96 [0.64, 1.44], p¼0.85) were also non-signiﬁ-
cant. Multivariate Cox model with the propensity risk score
applied suggest that in a subset of patients with high clinical
disease risk and non-adverse cytogenetics, the higher dose
busulfan RIC regimen may be of beneﬁt (2-year PFS, HR 0.54
[0.29, 1.03], p¼.062). For the majority of patients with MDS/
AML undergoing Bu/Flu RIC PBSCT, however, the dose of
busulfan (3.2 mg/kg vs 6.4 mg/kg) is not associated with
signiﬁcant differences in overall outcomes.12
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There have been a few multicenter or registry data
assessing the feasibility of unrelated donors (URD) in acute
myeloid leukemia (AML) compared to HLA-matched sibling
donors (MSD). These studies suggest that MSD and HLA-matched URD have comparable outcomes. However, the
small number of patients in ﬁrst complete remission (CR1)
and the lack of high-resolution HLA typing in these studies
make it difﬁcult to clearly determine the role of 8/8-matched
URD in patients with AML CR1. Furthermore, using 8/8-
matched URD is not currently standard practice in patients
with AML CR1 having intermediate cytogenetics, particularly
those without poor risk features, when MSD are not avail-
able. These patients are also candidates for non-allogeneic
stem cell transplantation (allo-SCT) therapy, such as autolo-
gous peripheral blood stem cell transplantation (auto-
PBSCT). In order to clarify the role of 8/8-mateched URD in
these patients, transplantation outcomes should be
compared with non-allo-SCT therapy as well as MSD.
Between 2002 and 2009, 567 adult patients with AML
underwent transplantation from MSD, URD, and autologous
sources. According to the risk-adapted treatment strategy,
AML CR1 with intermediate cytogenetics received allo-SCT as
a post-remission treatment, if MSD or 8/8-matched URD was
available.Patientswithnoavailabledonor receivedautologous
transplantation. To determine the role of 8/8-matchedURDon
transplantation outcomes in patients with intermediate
cytogenetics, we evaluated 288 patients with intermediate
cytogeneticswhounderwent transplantation fromautologous
sources (n¼89)orallogeneicdonors (n¼199) consistingof8/8-
matched URD (n¼54) and MSD (n¼145) at CR1.
In multivariate analyses, 8/8-matched URD had compa-
rable 6-year overall survival (OS, P¼0.997), disease-free
survival (DFS, P¼0.951), and relapse (P¼0.672) to MSD,
whereas 8/8-matched URD had a higher OS (P¼0.070) and
DFS (P¼0.035) with lower relapse (P¼0.009) than autologous
transplantation. No difference in non-relapse mortality was
observed according to donor type. Notably, these equivalent
or superior outcomes of 8/8-matched URD compared with
MSD or autologous transplantation, respectively, were
particularly evident in patients without poor risk features
(n¼200), such as older age, hyperleukocytosis at diagnosis,
and myelodysplasia-related changes, who are not usual
candidates for URD transplantation.
In conclusion, this study conﬁrmed the comparable
outcomes of 8/8-matched URD with MSD in AML CR1 with
intermediate cytogenetics. Additionally, this study strongly
suggests that 8/8-matched URD is preferable to auto-PBSCT in
AML CR1 with intermediate cytogenetics, when MSD are not
available. Finally, our data indicate that 8/8-matched URD are
feasiblenextoption inAMLCR1with intermediate cytogenetics,
when lacking MSD, even in patients without poor risk features.13
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We developed a 2-step approach to myeloablative hap-
loidentical HSCT in which patients receive a large ﬁxed dose
of cyclophosphamide (CY)-tolerized T cells separately frm
the HSC infusion in the hopes of accelerating post HSCT
immune reconstitution (IR). The uniformity of the T cell
dosing facilitates comparison of patients without (low risk)
and with (high risk) active malignancy at HSCT to ascertain
the impact of disease status at HSCT on IR with fewer con-
founding effects from conditioning or T cell dosing.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S116We analyzed IR at day þ28 in patients receiving 2 step
myeloablative haploidentical HSCT. All patients received 12
Gy of total body irradiation followed by 2 x 108 CD3þ cells/kg
donor T cells (HSCT step 1). CY 60 mg/kg/d x 2 was given
starting 2 or 3 days after the T cell infusion in the low and
high risk groups respectively. Tacrolimus and MMF were
begun on day -1. A CD 34 selected product was infused on
day 0 (HSCT step 2) with median CD34 doses of 5.8 and 5.2 x
106/kg in the low and high-risk groups respectively.
19 patients with AML (9), ALL (7), MDS (1), and NHL (2)
without disease, and 16 patients with AML (10), ALL (2), MDS
(3), and T cell NHL (1) with active disease at HSCT were
analyzed. A 17th patient in the high risk group died prior to
engraftment and was not fully evaluable. Outcomes for the
low and high risk groups respectively with 2-24 months
follow-up (median of 9 in each group) were: no rejections;
ANC >500: 11 versus 12 days; grades III-IV GVHD: 5.2%
versus 18.7%; mortality from GVHD 0% versus 6.2%; infec-
tious mortality: 0% versus 12.5%; non-infectious regimen-
related mortality: 0% versus 11.7%; mortality from relapse;
5.2% versus 18.7%; Overall survival: 94.8% versus 52.9%. By
day þ28, all patients had achieved CR and >95% donor
marrow chimerism. Compared to our experience with T cell
depleted (TCD) HSCT, improved T and NK cell IR was
observed, although the low risk group had higher median
numbers of T cells. Conversely, higher numbers of CD56bright
NK cells were present in the high risk group.
Compared to TCD approaches at our institution and
others, the 2 step approach allows for stronger early IR with
low infectious mortality in patients without and with active
malignancy at HSCT. IR was more robust in patients without
active disease. IR in the higher risk groupmay be hindered by
less hospitable marrow stroma and a greater baseline
inﬂammation related to the active malignancy and exacer-
bated by the HSCT. The increased rate of signiﬁcant GVHD
and the prominence of NKbright cells, which are strong
producers of cytokines, may reﬂect this higher state of
inﬂammation. In addition, differences in the degree of T cell
eradication by CY, based on T cell responses to malignancy or
the longer period of T cell activation in the high risk regimen,
may account for variations in IR between the groups.
Recognition of the differences in early IR amongst speciﬁc
patient populations may help optimize post HSCT care.
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Disease relapse after allogeneic hematopoietic stem cell
transplantation (HSCT) is the most important cause of
treatment failure. The mechanisms of leukemia relapse after
allogeneic stem cell transplantation remain elusive. Loss of
HLA class I antigens has been associatedwith disease relapse,
tumor progression and metastasis in solid tumors and has
been shown to be the direct consequence of selective pres-
sure mediated by T cells. We aimed to detect if changes in
HLA antigens occurs and is responsible for leukemia relapse.
We reviewed patients who relapsed post allogeneic stem
cell transplantation (allo-HSCT) for acute myeloid leukemia
(AML) or myelodysplastic syndrome and conducted post-
transplantation studies that included morphologic exami-
nation of bone marrow and HLA typing. Donor and recipient
blood specimens, which were collected pre-transplant and
post-relapse, were typed at intermediate- and high-resolu-
tion for HLA-A, -B, -C, -DRB1, and -DQB1 loci. A leukemia-
enriched population was isolated from peripheral blood
using a CD3þ/CD19þ depletion technique using MACs (Mil-
tenyi, Auburns CA). HLA typing was performed for all
samples either prospectively prior to transplantation and on
archived samples at the time of relapse by polymerase chain
reaction (PCR) ampliﬁcation and oligonucleotide hybridiza-
tion using molecular methods. We compared pre-transplant
and post-relapse specimens with the specimen at diagnosis
to evaluate the loss of heterozygosity (LOH) in blasts.
We identiﬁed 71 patients (median age: 51, 18-67; 48%
male)who relapsed after allo-HSCTand had samples stored at
the time of relapse. Sixty one (86%) transplantations were
matched for 10/10 HLA alleles and 10 (14%) for 9/10 alleles.
Eleven patients (15%) underwent transplantation in ﬁrst
remission (CR1), 15 (21%) in CR2, and 45 (63%) patients had
relapsed AML or primary induction failure. Conditioning
regimen consisted of a myeloablative regimen in 46 patients
(65%) and reduce intensity regimen in 25 patients (35%). The
source of stem-cells was peripheral blood in 47 (66%) and
bone marrow in 24 (34%). LOH in relapsed blasts was pre-
sented inonlyonecaseafterHSCT; in thispatientLOHwasalso
observed in the blasts collected in a pre-transplant specimen.
In conclusion, contrasting with the frequent ﬁnding of
LOH in relapse blasts after HSCT in haploidentical trans-
plantation followed by donor T-cell infusion, LOH in relapse
blasts is not common in T cell-replete matched HSCT. LOH
does not appear to be a dominant escape mechanism for
relapse in allogeneic HSCTwith a closely HLAmatched donor.15
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Although non-myelaoblative conditioning regimens have
proven successful in obtaining engraftment and reducing the
toxicity of allogeneic transplant, improvements are still
needed to improve engraftment rates as well as limit the
incidence of graft versus host disease. Methods to improve
engraftment without added toxicity are especially desirable
in the non malignant setting. Agonists of the Gs-coupled
